After successfully surpassing the previous swing high with considerable volume, attaining a fresh 52-week peak of $2.85, and witnessing the 50-day moving averages intersecting the 150 and 200 SMAs, ATAI appears poised for a reversal from its downtrend. **Potential Scenarios:** **Scenario 1: Triangular Consolidation (Orange)** ATAI may undergo consolidation...
Compass Pathways appears to have completed an impulsive 5-wave move to the upside, signaling significant strength in its recent price action. The peak of this move, reaching $12.75, is notably identified as the B wave within an extended flat correction, potentially forming part of a larger 5-wave pattern. In anticipation of a corrective phase, I anticipate a...
After closely monitoring psychedelic stocks for approximately six months, my attention has been drawn to ATAI. Despite enduring a challenging period over the past couple of years, the stock appears to be signaling a potential turnaround. Volume Analysis A notable observation is the diminishing volume during each downturn, coupled with a substantial surge in...
PSIL etf looks to be breaking out above the descending wedge it has been consolidating in. Top holding for the ETF (CYBN) is holding a meeting on Nov 30, 2023 to go over results of their clinical study on depression. Could be a breakout time for the psychedelic sector. Waiting for some confirmation on a breakout, and could take profit at 2.25 level. Disclosure:...
Trading at cash value (as of last financials). In historical support area. Active share buyback program. Good news flow. History of big bounces.
Will it pull up the AdvisorShares Psychedelics ETF? Strength in the #Biotech sector would also be a friendly situation. here are the top holdings: CMPS COMPASS PATHWAYS PLC 13.12% ATAI ATAI LIFE SCIENCES NV 9.73% CYBN CYBIN INC 7.97% SEEL SEELOS THERAPEUTICS INC 6.90% ITCI INTRA-CELLULAR THERAPIES INC 6.44% HUGE FSD PHARMA INC-CLASS B 5.82% SAGE SAGE...
Psychedelics space has seen some multi-baggers in the span of the last 2 weeks, suggesting investors are once again starting to pour money into speculative shroom stocks. CSE:LVT is deeply oversold (RSI @ 22.69), hitting all time lows. The company is deeply fundamentally undervalued: - $1.87M market cap - Raised $1.5M at 0.20 in February - Generating revenue of...
psychedelic is the future for mental health. I don't understand why the chart doesn't move but it will be because nothing else can heal the mental illness. At this moment we only have 20 years of Internet. We need to go forward. Psychotherapy doesn't work because sometimes even the client doesn't know what he have. I don't say that compass pathway will be the...
Beyond the successful breakout of the stochastic AND the crossover of the MACD, MindMed had a positive earnings report that beat expectations. All of the pieces are in play for this pattern to play out against expectations - and the break to the upside seems imminent. You don't have to (and legally shouldn't) listen to me, but I'm sitting happily on my...
Hello bulls, This one is a short-term play and can't much be said about it. After CMPS crushed, price dropped to 12$ and then due to Macro economical panic, crabbed around 11$. This is good that it's crabbing around 11$ because the next steps are the slow stairs to the 15$. Volume on last hour of December 3 indicates strong interest in 10.5-11$, meaning any...
As the chart shows, the most beautiful falling wedge pattern right into a key support. Numinus likely to rocket back to previous ATH offering traders a chance at 400% gains - SHORT TERM! Note: Numinus just applied to be listed on the Toronto Stock Exchange (TSX) pending some conditions. Add this Psychedelic leader to your portfolio. Similar stocks: CMPS, ATAI,...
Quietly meeting or exceeding all business targets and doing some fantastic work in the space. Here's an opportunity that doesn't come by every day.
NUMI could be in the midst of a Wykoff accumulation. ^ means a pro, v means a con. I am trying to look at both sides to reduce emotionally-blinded decision making. Looking from far, there is systematic market risk: v institutions adopting Bitcoin, resulting in broad market exposure to USDT fraud risk and Bitcoin volatility v GME apes stressing underlying...
Wait it out. The future is bright & no need to rush. FOMO investing is a disaster. Small caps with revenue growth & profits NOW matter most. *rising rate environment $GNLN #thegem #cannabisreform
RSI below 20. Raised $11.5M at $1.07 in January and presents 50% discount at current levels. Good news flow. Psychedelics sector is getting some traction again.
MNMD still hanging out around this 382 fib line. Wondering if the upcoming Atai IPO will help or hurt things. "Psychadelic penny stocks are performing well as many companies in the niche are growing in both size and popularity. Its latest update comes from May 26th when the company published its first pharmacogenetics data report on LSD in collaboration with...
This psychedelics play has been selling off after announcing a private placement at .40. Just out of oversold area and close to completing a bullish MACD cross. My guess is that some of the financing participants are selling their .40 shares and keeping the free .50 warrant which creates an opportunity to get in at discount to financing. Management is highly...
I mean look, I know it's all a bunch of speculative mumbo jumbo, but some of these other psychedelic companies have like, BILLION dollar market caps! That's crazy, right? I mean sure, they will certainly disrupt an incredibly-entrenched industry, but it's going to take time for that to happen... That said, I think there are going to be baby steps, which means...